Published in J Exp Med on January 18, 1999
MIF signal transduction initiated by binding to CD74. J Exp Med (2003) 4.79
The enigma of sepsis. J Clin Invest (2003) 4.32
CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity (2006) 3.38
Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci U S A (2001) 3.29
The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci U S A (2003) 2.29
A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock. J Exp Med (2000) 2.17
A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice. J Immunol (2010) 1.91
Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci U S A (2005) 1.79
A critical role for the host mediator macrophage migration inhibitory factor in the pathogenesis of malarial anemia. J Exp Med (2006) 1.61
Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc Natl Acad Sci U S A (2002) 1.55
Cytokines in sepsis: potent immunoregulators and potential therapeutic targets--an updated view. Mediators Inflamm (2013) 1.54
Spermine protects mice against lethal sepsis partly by attenuating surrogate inflammatory markers. Mol Med (2009) 1.52
Syndecan-1 shedding facilitates the resolution of neutrophilic inflammation by removing sequestered CXC chemokines. Blood (2009) 1.46
A tautomerase-null macrophage migration-inhibitory factor (MIF) gene knock-in mouse model reveals that protein interactions and not enzymatic activity mediate MIF-dependent growth regulation. Mol Cell Biol (2009) 1.43
Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ (2003) 1.37
Role of monocyte-acquired hemozoin in suppression of macrophage migration inhibitory factor in children with severe malarial anemia. Infect Immun (2006) 1.36
Migration-inhibitory factor gene-deficient mice are susceptible to cutaneous Leishmania major infection. Infect Immun (2001) 1.36
Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev Mol Med (2008) 1.30
Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock (2009) 1.29
Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids. Clin Exp Immunol (2001) 1.29
The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF). Proc Natl Acad Sci U S A (2011) 1.29
Alternative chemical modifications reverse the binding orientation of a pharmacophore scaffold in the active site of macrophage migration inhibitory factor. J Biol Chem (2007) 1.28
Functional characterization of the Plasmodium falciparum and P. berghei homologues of macrophage migration inhibitory factor. Infect Immun (2006) 1.23
Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol (2008) 1.23
The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia. FASEB J (2009) 1.22
Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Arthritis Res Ther (2006) 1.19
The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. J Clin Invest (2000) 1.19
Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity against Salmonella typhimurium. Proc Natl Acad Sci U S A (2002) 1.18
Release of macrophage migration inhibitory factor and CXCL8/interleukin-8 from lung epithelial cells rendered necrotic by influenza A virus infection. J Virol (2002) 1.16
Critical advances in septicemia and septic shock. Crit Care (2000) 1.16
Macrophage migration inhibitory factor promotes cell death and aggravates neurologic deficits after experimental stroke. J Cereb Blood Flow Metab (2010) 1.13
Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo. Am J Pathol (2003) 1.12
Circulating inflammatory mediators and organ dysfunction after cardiovascular surgery with cardiopulmonary bypass: a prospective observational study. Crit Care (2006) 1.12
MIF (macrophage migration inhibitory factor) promoter polymorphisms and susceptibility to severe malarial anemia. J Infect Dis (2009) 1.11
Inhibition of macrophage migration inhibitory factor ameliorates ocular Pseudomonas aeruginosa-induced keratitis. PLoS Pathog (2010) 1.10
Macrophage CD74 contributes to MIF-induced pulmonary inflammation. Respir Res (2009) 1.10
Staphylococcal enterotoxin B-induced acute inflammation is inhibited by dexamethasone: important role of CXC chemokines KC and macrophage inflammatory protein 2. Infect Immun (2003) 1.08
Direct modification of the proinflammatory cytokine macrophage migration inhibitory factor by dietary isothiocyanates. J Biol Chem (2009) 1.08
Macrophage migration inhibitory factor plays a critical role in mediating protection against the helminth parasite Taenia crassiceps. Infect Immun (2003) 1.07
Macrophage migration inhibitory factor contributes to host defense against acute Trypanosoma cruzi infection. Infect Immun (2006) 1.05
Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation. Exp Mol Pathol (2009) 1.04
Macrophage migration inhibitory factor (MIF) is critical for the host resistance against Toxoplasma gondii. FASEB J (2008) 1.04
Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects. Eur J Immunol (2013) 1.04
Macrophage migration inhibitory factor in patients with preterm parturition and microbial invasion of the amniotic cavity. J Matern Fetal Neonatal Med (2005) 1.01
D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family. Cytokine (2012) 1.01
Macrophage migration inhibitory factor (MIF) is a critical mediator of the innate immune response to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2013) 1.00
Macrophage migration inhibitory factor (MIF): a key player in protozoan infections. Int J Biol Sci (2011) 0.99
Macrophage migration inhibitory factor-knockout mice are long lived and respond to caloric restriction. FASEB J (2010) 0.99
Deficiency of the macrophage migration inhibitory factor gene has no significant effect on endotoxaemia. Immunology (2000) 0.99
Macrophage migration inhibitory factor contributes to the development of acute dextran sulphate sodium-induced colitis in Toll-like receptor 4 knockout mice. Clin Exp Immunol (2005) 0.98
Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis. Cytokine (2013) 0.98
Null mutation for macrophage migration inhibitory factor (MIF) is associated with less aggressive bladder cancer in mice. BMC Cancer (2007) 0.98
Macrophage migration inhibitory factor mediates hypoxia-induced pulmonary hypertension. Mol Med (2012) 0.96
MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models. Cell Div (2007) 0.96
Macrophage migration inhibitory factor of the parasitic nematode Trichinella spiralis. Biochem J (2001) 0.94
Lung-derived macrophage migration inhibitory factor in sepsis induces cardio-circulatory depression. Surg Infect (Larchmt) (2007) 0.94
A small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease. FASEB J (2010) 0.93
MIF produced by bone marrow-derived macrophages contributes to teratoma progression after embryonic stem cell transplantation. Cancer Res (2012) 0.93
Plasmodium yoelii macrophage migration inhibitory factor is necessary for efficient liver-stage development. Infect Immun (2012) 0.93
High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation. Inflamm Allergy Drug Targets (2010) 0.92
Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. Immunology (2008) 0.91
MIF homologues from a filarial nematode parasite synergize with IL-4 to induce alternative activation of host macrophages. J Leukoc Biol (2009) 0.91
Lack of macrophage migration inhibitory factor in mice does not affect hallmarks of the inflammatory/immune response during the first week after stroke. J Neuroinflammation (2011) 0.91
Increased plasma thioredoxin levels in patients with sepsis: positive association with macrophage migration inhibitory factor. Intensive Care Med (2009) 0.90
Macrophage migration inhibitory factor induces cardiomyocyte apoptosis. Biochem Biophys Res Commun (2008) 0.90
Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the β-sheet structure of MIF. J Biol Chem (2012) 0.90
Mast cells aggravate sepsis by inhibiting peritoneal macrophage phagocytosis. J Clin Invest (2014) 0.89
Elevated levels of macrophage migration inhibitory factor (MIF) in the plasma of HIV-1-infected patients and in HIV-1-infected cell cultures: a relevant role on viral replication. Virology (2010) 0.89
Macrophage migration inhibitory factor promotes clearance of pneumococcal colonization. J Immunol (2014) 0.88
Macrophage migration inhibitory factor regulates interleukin-6 production by facilitating nuclear factor-kappa B activation during Vibrio vulnificus infection. BMC Immunol (2010) 0.88
Inactivation of tautomerase activity of macrophage migration inhibitory factor by sulforaphane: a potential biomarker for anti-inflammatory intervention. Cancer Epidemiol Biomarkers Prev (2011) 0.87
The role of MIF in type 1 and type 2 diabetes mellitus. J Diabetes Res (2014) 0.87
MIF synergizes with Trypanosoma cruzi antigens to promote efficient dendritic cell maturation and IL-12 production via p38 MAPK. Int J Biol Sci (2011) 0.87
Brain miffed by macrophage migration inhibitory factor. Int J Cell Biol (2012) 0.86
Improved resistance to bacterial superinfection in mice by treatment with macrophage migration inhibitory factor. Infect Immun (2005) 0.86
Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation. J Inflamm Res (2010) 0.86
Macrophage migration inhibitory factor (MIF) is essential for inflammatory and neuropathic pain and enhances pain in response to stress. Exp Neurol (2012) 0.86
The role of macrophage migration inhibitory factor in Alzheimer's disease. Mol Med (2010) 0.86
Macrophage migration inhibitory factor is required for recruitment of scar-associated macrophages during liver fibrosis. J Leukoc Biol (2014) 0.86
Role of macrophage migration inhibitory factor in the Th2 immune response to epicutaneous sensitization. J Clin Immunol (2011) 0.85
Macrophage migration inhibitory factor deficiency in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol (2014) 0.85
Macrophage migration inhibitory factor is a novel determinant of cigarette smoke-induced lung damage. Am J Respir Cell Mol Biol (2014) 0.85
The role of macrophage migration inhibitory factor in the cascade of events leading to reperfusion-induced inflammatory injury and lethality. Am J Pathol (2007) 0.85
Benzisothiazolones as modulators of macrophage migration inhibitory factor. Bioorg Med Chem Lett (2011) 0.85
Renal replacement therapy neutralizes elevated MIF levels in septic shock. J Intensive Care (2016) 0.84
Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model. Br J Cancer (2012) 0.84
Effect of macrophage migration inhibitory factor (MIF) in human placental explants infected with Toxoplasma gondii depends on gestational age. Am J Pathol (2011) 0.84
A novel allosteric inhibitor of macrophage migration inhibitory factor (MIF). J Biol Chem (2012) 0.84
Deletion of macrophage migration inhibitory factor worsens stroke outcome in female mice. Neurobiol Dis (2013) 0.83
Role of macrophage migration inhibitory factor in otitis media with effusion in adults. Clin Diagn Lab Immunol (2003) 0.83
Differential and cell-type specific regulation of responses to Toll-like receptor agonists by ISO-1. Immunology (2008) 0.83
Independent roles of macrophage migration inhibitory factor and endogenous, but not exogenous glucocorticoids in regulating leukocyte trafficking. Microcirculation (2009) 0.83
MIF: Implications in the Pathoetiology of Systemic Lupus Erythematosus. Front Immunol (2015) 0.82
Macrophage migration inhibitory factor induces vascular leakage via autophagy. Biol Open (2015) 0.82
MIF participates in Toxoplasma gondii-induced pathology following oral infection. PLoS One (2011) 0.82
Impact of MIF gene promoter polymorphism on F508del cystic fibrosis patients. PLoS One (2014) 0.81
The role of macrophage migration inhibitory factor in maintaining the immune privilege at the fetal-maternal interface. Semin Immunopathol (2007) 0.81
Spatiotemporal patterns of macrophage migration inhibitory factor (Mif) expression in the mouse placenta. Reprod Biol Endocrinol (2010) 0.81
Imipramine reverses depressive-like parameters in pneumococcal meningitis survivor rats. J Neural Transm (Vienna) (2011) 0.81
Macrophage migration inhibitory factor in protozoan infections. J Parasitol Res (2012) 0.81
Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem (1982) 27.26
The pathophysiology of tumor necrosis factors. Annu Rev Immunol (1992) 8.38
Endotoxins and disease mechanisms. Annu Rev Med (1987) 6.07
MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature (1993) 5.60
The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med (1994) 5.55
MIF as a glucocorticoid-induced modulator of cytokine production. Nature (1995) 5.21
Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. J Exp Med (1987) 4.63
Superantigens and their potential role in human disease. Adv Immunol (1993) 3.88
The C5a chemoattractant receptor mediates mucosal defence to infection. Nature (1996) 3.73
Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry (1994) 3.58
Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin. Infect Immun (1986) 3.42
Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity (1996) 3.33
Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice. J Exp Med (1994) 3.32
Growth factor-induced delayed early response genes. Mol Cell Biol (1992) 3.03
Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med (1997) 2.98
Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest. J Immunol (1994) 2.87
Enhancement of growth of virulent strains of Escherichia coli by interleukin-1. Science (1991) 2.37
Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol (1997) 1.86
The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med (1997) 1.86
Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-alpha. J Immunol (1998) 1.63
A macrophage migration inhibitory factor is expressed in the differentiating cells of the eye lens. Proc Natl Acad Sci U S A (1993) 1.54
Hepatic and extrahepatic pathobiology of bacterial lipopolysaccharides. Pharmacol Rev (1993) 1.45
MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. FASEB J (1996) 1.44
Molecules and mechanisms operating in septic shock: lessons from knockout mice. Immunol Today (1997) 1.38
Tumor necrosis factor alpha binding to bacteria: evidence for a high-affinity receptor and alteration of bacterial virulence properties. Infect Immun (1993) 1.36
Effect of anti-macrophage migration inhibitory factor antibody on lipopolysaccharide-induced pulmonary neutrophil accumulation. Am J Respir Crit Care Med (1998) 1.35
Protective effect on Leishmania major infection of migration inhibitory factor, TNF-alpha, and IFN-gamma administered orally via attenuated Salmonella typhimurium. J Immunol (1998) 1.15
Mucosal exudation associated with a pulmonary delayed-type hypersensitivity reaction in the mouse. Role for the tachykinins. J Immunol (1994) 0.99
Structural characterization and chromosomal location of the mouse macrophage migration inhibitory factor gene and pseudogenes. Genomics (1995) 0.94
Evidence for the presence of macrophage migration inhibitory factor in murine reproductive organs and early embryos. Immunol Lett (1996) 0.92
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 17.13
Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A (1966) 12.29
CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (1996) 11.37
Alterations of macrophage functions by mediators from lymphocytes. J Exp Med (1971) 7.95
Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell (1998) 7.46
Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med (1998) 6.52
Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature (1995) 5.15
Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell (1999) 4.97
Genetic variation of Drosophila melanogaster natural populations. Trends Genet (1988) 4.62
Suppression of delayed hypersensitivity in vitro by inhibition of protein synthesis. J Exp Med (1965) 4.62
Xenopus chordin: a novel dorsalizing factor activated by organizer-specific homeobox genes. Cell (1994) 4.53
The enhancement of macrophage bacteriostasis by products of activated lymphocytes. J Exp Med (1973) 4.51
Metabolic regulation of brain Abeta by neprilysin. Science (2001) 4.47
Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature (1996) 4.41
A new method for the purification of human eosinophils and neutrophils, and a comparison of the ability of these cells to damage schistosomula of Schistosoma mansoni. J Immunol (1979) 4.17
Characterization of a lymphocyte factor which alters macrophage functions. J Exp Med (1973) 3.98
Leukotactic factor produced by sensitized lymphocytes. Science (1969) 3.95
Dorsoventral patterning in Xenopus: inhibition of ventral signals by direct binding of chordin to BMP-4. Cell (1996) 3.91
Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med (2000) 3.84
An in vitro assay for cellular hypersensitivity in man. J Immunol (1970) 3.73
The C5a chemoattractant receptor mediates mucosal defence to infection. Nature (1996) 3.73
Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol (2000) 3.61
Obesity and inequities in health in the developing world. Int J Obes Relat Metab Disord (2004) 3.49
Cellular hypersensitivity and immunity. Inhibition of macrophage migration and the lymphocyte mediators. Prog Allergy (1972) 3.47
Macrophage migration. Fed Proc (1990) 3.39
Studies on mediator production by highly purified human T and B lymphocytes. J Exp Med (1974) 3.38
Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med (1996) 3.33
The production by antigen-stimulated lymphocytes of a leukotactic factor distinct from migration inhibitory factor. Cell Immunol (1970) 3.17
The chemotactic receptor for human C5a anaphylatoxin. Nature (1991) 3.15
SAP controls T cell responses to virus and terminal differentiation of TH2 cells. Nat Immunol (2001) 2.95
rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis (1996) 2.93
Studies on migration inhibitory factor (MIF): recovery of MIF activity after purification by gel filtration and disc electrophoresis. Cell Immunol (1970) 2.86
Humoral and cellular sensitivity to collagen in type II collagen-induced arthritis in rats. J Clin Invest (1978) 2.84
Passive transfer by cells of type II collagen-induced arthritis in rats. J Clin Invest (1978) 2.81
Damage to schistosomula of Schistosoma mansoni induced directly by eosinophil major basic protein. J Immunol (1979) 2.81
Development of an extremely wear-resistant ultra high molecular weight polyethylene for total hip replacements. J Orthop Res (1999) 2.81
Regulation of neural induction by the Chd and Bmp-4 antagonistic patterning signals in Xenopus. Nature (1995) 2.75
Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. J Exp Med (1997) 2.75
PAR-1 is a Dishevelled-associated kinase and a positive regulator of Wnt signalling. Nat Cell Biol (2001) 2.69
Expression and biologic characterization of the murine chemokine KC. J Immunol (1995) 2.66
Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. Antimicrob Agents Chemother (1999) 2.63
A conserved system for dorsal-ventral patterning in insects and vertebrates involving sog and chordin. Nature (1995) 2.58
HIV-1 entry and macrophage inflammatory protein-1beta-mediated signaling are independent functions of the chemokine receptor CCR5. J Biol Chem (1997) 2.55
Cerberus is a head-inducing secreted factor expressed in the anterior endoderm of Spemann's organizer. Nature (1996) 2.54
Cellular sensitivity to collagen in rheumatoid arthritis. N Engl J Med (1978) 2.50
Infection of human cells by dengue virus is modulated by different cell types and viral strains. J Virol (2000) 2.49
Cleavage of Chordin by Xolloid metalloprotease suggests a role for proteolytic processing in the regulation of Spemann organizer activity. Cell (1997) 2.44
Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells. Proc Natl Acad Sci U S A (1994) 2.41
Essential role for Gab2 in the allergic response. Nature (2001) 2.32
Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol (1986) 2.31
The role of brain-derived neurotrophic factor receptors in the mature hippocampus: modulation of long-term potentiation through a presynaptic mechanism involving TrkB. J Neurosci (2000) 2.28
A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol (1998) 2.28
Impairments in high-frequency transmission, synaptic vesicle docking, and synaptic protein distribution in the hippocampus of BDNF knockout mice. J Neurosci (1999) 2.26
Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A (1989) 2.24
A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature (2000) 2.24
Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol (2001) 2.20
The compartmentalization of antigen-reactive lymphocytes in desensitized guinea pigs. J Exp Med (1971) 2.18
Metabolic and functonal studies on activated mouse macrophages. J Exp Med (1973) 2.17
Leishmania species: models of intracellular parasitism. J Cell Sci (1999) 2.13
Antibody-dependent eosinophil-mediated damage to 51Cr-labeled schistosomula of Schistosoma mansoni: damage by purieid eosinophils. J Exp Med (1977) 2.06
Neurogenic amplification of immune complex inflammation. Science (1996) 2.05
Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239. J Virol (1997) 2.04
BMP-binding modules in chordin: a model for signalling regulation in the extracellular space. Development (2000) 2.02
Macrophage activation by lymphocyte mediators. Fed Proc (1975) 1.99
Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. Am J Trop Med Hyg (1998) 1.99
Host-plant specialization in the Drosophila melanogaster species complex: a physiological, behavioral, and genetical analysis. Proc Natl Acad Sci U S A (1991) 1.98
Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med (2006) 1.97
Similarities and differences in latitudinal adaptation of two Drosophila sibling species. Nature (1975) 1.96
Tumor necrosis factor enhances eosinophil toxicity to Schistosoma mansoni larvae. Proc Natl Acad Sci U S A (1986) 1.93
Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis (2005) 1.91
Evolution in a cosmopolitan species: genetic latitudinal clines in Drosophila melanogaster wild populations. Experientia (1975) 1.91
Immunochemical studies on the specificity of cellular hypersensitivity. The in vitro inhibition of peritoneal exudate cell migration by cehmically defined antigens. J Exp Med (1968) 1.90
The ultimate speed of magnetic switching in granular recording media. Nature (2004) 1.89
Monoclonal antibodies that distinguish between New World species of Leishmania. Nature (1981) 1.89
CD4-independent binding of SIV gp120 to rhesus CCR5. Science (1997) 1.87
Lymph node trafficking and antigen presentation by endobronchial eosinophils. J Clin Invest (2000) 1.85
Impaired inflammatory responses in the reverse arthus reaction through genetic deletion of the C5a receptor. J Exp Med (1997) 1.83
Characterization of migration inhibitory factor (MIF) from guinea pig lymphocytes stimulated with concanavalin A. J Immunol (1972) 1.82
A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry. J Biol Chem (2000) 1.80
Mediators produced by sensitized lymphocytes. Fed Proc (1972) 1.79
Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol (1997) 1.77
Mitochondrial DNA variability in Drosophila simulans: quasi absence of polymorphism within each of the three cytoplasmic races. Heredity (Edinb) (1988) 1.76
Microbiological spectrum of septicemia and peritonitis in nephrotic children. Pediatr Nephrol (1999) 1.75
Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J Immunol (2001) 1.74
Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am J Transplant (2010) 1.74
Activation of human blood monocytes by products of sensitized lymphocytes. J Clin Invest (1974) 1.73
The murine interleukin 8 type B receptor homologue and its ligands. Expression and biological characterization. J Biol Chem (1994) 1.72
Isolation of three separate anaphylatoxins from complement-activated human serum. Mol Cell Biochem (1981) 1.70
Are elevated liver enzymes and bilirubin levels significant after laparoscopic cholecystectomy in the absence of bile duct injury? Ann Surg (1994) 1.69
Maternal-fetal relation. Absence of an immunologic blocking factor from the serum of women with chronic abortions. N Engl J Med (1976) 1.69
Schistosoma mansoni: rapid isolation and purification of schistosomula of different developmental stages by centrifugation on discontinuous density gradients of Percoll. Exp Parasitol (1982) 1.66
Identification and distribution of New World Leishmania species characterized by serodeme analysis using monoclonal antibodies. Am J Trop Med Hyg (1987) 1.65
Prevention of MIF activity by agents known to increase cellular cyclic AMP. J Immunol (1973) 1.64